28.07
Avalyn Pharma Inc (AVLN) 最新ニュース
IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace
Avalyn Pharma (AVLN) Earnings Date and Reports 2026 - MarketBeat
Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead - inkl
Morgan Stanley Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $53 - 富途牛牛
Avalyn Pharma Inc. 2026 Q1 Financial Report and Material Risks Overview - Minichart
Avalyn Pharma 1Q Loss $26.9M >AVLN - Moomoo
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
Avalyn Pharma Inc. 1Q 2026: Net income $(26.9M), EPS $(21.83) — 10-Q Summary - TradingView
Avalyn: Q1 Earnings Snapshot - marketscreener.com
AVLN: Q1 2026 net loss widened to $26.9M; IPO proceeds extend cash runway into 2029, but more funding needed - TradingView
Avalyn Pharma (Nasdaq: AVLN) widens Q1 loss but extends cash runway into 2029 - Stock Titan
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Avalyn Pharma (AVLN) Stock Chart and Price History 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga
Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves - Yahoo Finance
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avalyn Pharma Inc.: Target Price Consensus and Analysts Recommendations | AVLN | US05348Y1055 - marketscreener.com
Avalyn to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
AVLN Initiated Coverage by Morgan Stanley -- Price Target Set at $53 - GuruFocus
AVLN Initiates Coverage by Guggenheim -- Price Target Announced at $80 - GuruFocus
This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Jefferies Maintains AVALYN PHARMA INC(AVLN.US) With Buy Rating, Maintains Target Price $52 - 富途牛牛
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Guggenheim Initiates Avalyn Pharma at Buy With $80 Price Target - Moomoo
Morgan Stanley Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $53 - Moomoo
Jefferies Initiates Avalyn Pharma at Buy With $52 Price Target - Moomoo
Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating By Investing.com - Investing.com South Africa
Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating - Investing.com Australia
Avalyn Pharma (AVLN) Stock Forecast and Price Target 2026 - MarketBeat
Jefferies initiates Avalyn Pharma stock with buy on lung disease data - Investing.com India
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs By Investing.com - Investing.com Australia
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs - Investing.com UK
Jefferies Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $52 - Moomoo
AVLN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AVLN Technical Analysis | Trend, Signals & Chart Patterns | AVALYN PHARMA INC (NASDAQ:AVLN) - ChartMill
Avalyn Pharma to present 4-year AP01 data at EULAR conference By Investing.com - Investing.com South Africa
大文字化:
|
ボリューム (24 時間):